BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 20519274)

  • 1. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
    Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J; Dunn TA; Ewing CM; Walsh PC; Isaacs WB
    Prostate; 2003 Oct; 57(2):134-9. PubMed ID: 12949937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
    Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
    J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
    Wang LG; Liu XM; Kreis W; Budman DR
    Cancer Res; 1997 Feb; 57(4):714-9. PubMed ID: 9044850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of LMO2 expression in the progression of prostate cancer.
    Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
    J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 promotes prostate cancer progression.
    Fujita H; Koshida K; Keller ET; Takahashi Y; Yoshimito T; Namiki M; Mizokami A
    Prostate; 2002 Nov; 53(3):232-40. PubMed ID: 12386924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro].
    Deng G; Yu JH; Ye ZQ; Hu ZQ
    Zhonghua Nan Ke Xue; 2008 Feb; 14(2):116-21. PubMed ID: 18390174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray].
    Chen G; Geng J; Zhang YF
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1489-92. PubMed ID: 16061029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.
    Grzmil M; Voigt S; Thelen P; Hemmerlein B; Helmke K; Burfeind P
    Int J Oncol; 2004 Jan; 24(1):97-105. PubMed ID: 14654946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
    Tesan T; Gustavsson H; Welén K; Damber JE
    BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.